South Carolina Consortium of the Clinical Trials Network

南卡罗来纳州临床试验网络联盟

• 批准号: 7683877
• 负责人: KATHLEEN T. BRADY
• 金额: $ 125万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7683877
• 关键词: Adult; Adverse effects; Alcohol dependence; Alcohols; Area; Brain; CYP2B6 gene; Cannabinoids; Cessation of life; Cigarette; Cigarette Smoker; Classification; Clinical; Clinical Trials; Clinical Trials Network; Cocaine; Communication; Communities; Data Coordinating Center; Dependency; Effectiveness; Enrollment; Enzymes; Europe; Evidence based practice; Funding; Future; Genetic Research; Health Personnel; Individual; Intervention; Lead; Marijuana Smoking; Minority; Mission; Mississippi; Morbidity - disease rate; Multi-Institutional Clinical Trial; National Institute of Drug Abuse; Nicotine; Operative Surgical Procedures; Opiates; Participant; Pathway interactions; Pharmaceutical Preparations; Pharmacogenetics; Pharmacologic Substance; Pharmacotherapy; Placebos; Population; Population Study; Qualifying; Recovery; Rehabilitation therapy; Research; Research Infrastructure; Research Personnel; Research Training; Rewards; Role; Safety; Science; Site; Smoke; Smoking Cessation Intervention; Source; South Carolina; Substance Use Disorder; Substance abuse problem; Time; Training; Training Programs; U-Series Cooperative Agreements; United States; Withholding Treatment; Work; addiction; alcohol rehabilitation; base; cigarette smoking; clinical practice; craving; depression; drug of abuse; effective therapy; genetic variant; human subject; improved; member; mortality; programs; protocol development; receptor; response; rimonabant; smoking cessation; treatment response; urban area

The Clinical Trials Network (CTN) is a cooperative agreement between NIDA, treatment providers and researchers throughout the nation in which science is being utilized as a vehicle to improve the treatment of addictions. In the initial funding period, a valuable infrastructure with bidirectional communication between the treatment and research communities was established and a number of important clinical trials were conducted. The SC Node has been an enthusiastic and productive participant in these activities. In this proposal, the progress of the last four years and a plan for future activities is described. Over the next five years, we will continue to work closely with NIDA and colleagues nationwide in conducting rigorous, multi-site clinical trials and improving CTN efficiency. We will extend our efforts in important ways. The SC Node will be the Lead Node for a pharmacotherapy/depression (CTN0026) study awaiting implementation. We will extend our geographical reach by forming a consortium of CTPs from South Carolina, Georgia and Mississippi to facilitate dissemination efforts. We will add a research CTP from a large urban area (Atlanta, Georgia) to expand the diversity and volume of potential research participants. We will use the CTN as a platform for research by seeking non-CTN funding (i.e., pharmaceutical or other federal funds) to support studies to be conducted across several CTN sites. We will extend the use of the CTN as a platform for training by partnering with minority training initiatives and other training programs at MUSC. The specific aims of this proposal are: (1) To work collaboratively with NIDA, the newly established coordinating and data centers, and other CTN Nodes in improving the efficiency of CTN operations, conducting and directing multi-site clinical trials and dissemination efforts. (2) To form a consortium of CTPs throughout South Carolina, Georgia and Mississippi to facilitate the dissemination of evidence-based practice in the substance abuse area. (3) To increase the utilization of the CTN as a research platform by applying for monies from non-CTN sources. We will conduct/participate in at least three studies using the CTN as a research platform during the renewal period. (4) To increase the use of the CTN .as a training platform by partnering with existing research training programs at MUSC. We will involve at least one new trainee per year and apply for at least one minority supplement. (5) To promote the use of the CTN as a platform for genetics research. We have applied for funding for a pharmacogenetics study to be conducted within the CTN. The CTN provides a unique and exciting opportunity to work collaboratively with colleagues throughout the nation in bridging the gap between research and treatment, and in exploring effective treatments for individuals with substance use disorders. The SC Node is enthusiastic about continuing its active role in the CTN over the next five years.

临床试验网络（CTN）是NIDA，治疗提供者与研究人员之间的合作协议 在整个国家，科学被用作改善成瘾治疗的工具。在 初始资金期，这是一个有价值的基础设施，并在治疗与研究之间进行双向交流 建立了社区，并进行了许多重要的临床试验。 SC节点一直是 这些活动的热情和富有成效的参与者。在此提案中，过去四年的进展和 描述了未来活动的计划。在接下来的五年中，我们将继续与NIDA紧密合作 全国同事在进行严格的多站点临床试验并提高CTN效率。我们将扩展 我们以重要方式的努力。 SC节点将是药物疗法/抑郁症的铅节点（CTN0026） 研究等待实施。我们将通过从南方组建一个CTP联盟来扩展地理范围 卡罗来纳州，佐治亚州和密西西比州，以促进传播工作。我们将添加来自大型城市的研究CTP 区域（佐治亚州亚特兰大）扩大潜在研究参与者的多样性和数量。我们将使用CTN作为 通过寻求非CTN资金（即药物或其他联邦资金）来支持研究的研究平台 可以在几个CTN站点进行。我们将扩大CTN作为培训平台的使用 通过MUSC的少数民族培训计划和其他培训计划。该提案的具体目的是： （1）与NIDA，新建立的协调和数据中心以及其他CTN节点合作 提高CTN操作的效率，进行和指导多站点临床试验和传播工作。 （2）在整个南卡罗来纳州，佐治亚州和密西西比州组成一个CTP联盟，以促进传播 滥用药物的循证实践。 （3）通过申请非CTN来源的款项来增加CTN作为研究平台的利用。我们 将在续签期间使用CTN作为研究平台进行/参与至少三项研究。 （4）通过与现有的研究培训计划合作，以增加CTN的使用。 马斯克。我们每年至少要涉及一名新学员，并申请至少一种少数族裔补充。 （5）促进CTN用作遗传学研究的平台。我们已经申请了资金 药物遗传学研究将在CTN内进行。 CTN为与全国各地的同事合作提供了一个独特而激动人心的机会 弥合研究和治疗之间的差距，并在探索有效治疗的人时 使用疾病。 SC节点热衷于在未来五年内继续在CTN中发挥积极作用。